ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,171.00
0.84%
Dow Jones
38,786.65
0.29%
US Dollar vs MXN
16.8882
-0.56%
Brent Oil
83.265
0.17%
Bitcoin
63,120.43
-1.37%
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Immunome Inc (IMNM)

  7. Immunome Inc (IMNM) Noticias

IMNM Immunome Inc

15.29
-0.46 (-2.92%)
Última actualización: 14:32:27
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Immunome Inc IMNM NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
-0.46 -2.92% 15.29 14:32:27
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
15.75 15.12 16.1799 15.75
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
02/5/202407:00BWImmunome Appoints Kinney Horn as Chief Business Officer
25/4/202407:26BWImmunome Appoints Sandra M. Swain to Board of Directors
05/4/202407:00BWImmunome to Present Preclinical Data for IM-3050, Its Lead..
28/3/202415:02BWImmunome Reports Full Year 2023 Financial Results and..
26/3/202407:00BWImmunome Completes Acquisition of AL102, a Phase 3 Asset for..
07/3/202407:00BWImmunome to Participate in the Leerink Partners Global..
01/3/202407:00BWImmunome to Participate in the TD Cowen 44th Annual..
21/2/202420:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/2/202420:07EDGAR2Form 3 - Initial statement of beneficial ownership of..
20/2/202407:15BWImmunome Recognizes Ayala Pharmaceuticals’ Announced..
16/2/202415:05BWImmunome Announces Closing of Public Offering and Full..
14/2/202415:11EDGAR2Form 8-K - Current report
14/2/202415:09EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
13/2/202421:38BWImmunome Announces Pricing of Public Offering of Common..
13/2/202415:36EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
13/2/202415:10EDGAR2Form 8-K - Current report
13/2/202415:05BWImmunome Announces Proposed Public Offering of Common Stock
12/2/202413:10EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
06/2/202407:05EDGAR2Form 8-K - Current report
05/2/202407:00BWImmunome to Present at the Guggenheim Healthcare Talks 6th..
02/2/202415:04EDGAR2Form S-8 - Securities to be offered to employees in employee..
31/1/202419:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31/1/202419:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/1/202416:27EDGAR2Form 8-K - Current report
08/1/202406:05EDGAR2Form 8-K - Current report
08/1/202406:00BWImmunome Exclusively Licenses Zentalis ROR1 Antibody-Drug..
04/1/202416:40EDGAR2Form 3 - Initial statement of beneficial ownership of..
04/1/202407:00BWImmunome Appoints Phil Roberts as Chief Technical Officer
03/1/202407:00BWImmunome to Present at the 42nd Annual J.P. Morgan..
02/1/202407:05EDGAR2Form 8-K - Current report
02/1/202407:00BWImmunome Appoints Carol A. Schafer to Board of Directors
29/12/202316:00EDGAR2Form 8-K - Current report
26/12/202307:35EDGAR2Form 8-K - Current report
26/12/202307:30GLOBEAtreca Announces Asset Purchase Agreement for Sale of..
15/12/202318:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/12/202320:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/11/202323:15EDGAR2Form EFFECT - Notice of Effectiveness
22/11/202315:02EDGAR2Form 8-K/A - Current report: [Amend]
16/11/202315:08EDGAR2Form S-3 - Registration statement under Securities Act of..
15/11/202305:03EDGAR2Form 8-K - Current report
10/11/202307:00BWImmunome to Present at the Stifel 2023 Healthcare Conference
09/11/202315:52EDGAR2Form 8-K - Current report
09/11/202307:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202307:00BWImmunome Reports Third Quarter 2023 Financial Results
08/11/202307:30EDGAR2Form 8-K - Current report
08/11/202307:00BWImmunome Appoints Jean-Jacques Bienaimé to Board of..
31/10/202317:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31/10/202317:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31/10/202317:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/10/202307:00BWImmunome Appoints Bob Lechleider, M.D., as Chief Medical..

Su Consulta Reciente

NASDAQ
IMNM
Immunome
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados